Immunome, Inc. (IMNM) Stock Analysis

Q: What is the IMNM stock price target?

Take-profit $30.65 (+46.8% upside). Prior stop was $19.99.

Q: What are the risks of investing in IMNM?

Concentration risk — Pipeline: varegacestat; Quality below floor (1.7 < 4.0); Quality below floor (1.7 < 4.0); Momentum score 4.0/10 — below 4.5 minimum.

Q: Is IMNM overvalued or undervalued?

Immunome, Inc. trades at a P/E of N/A (forward -10.4). TrendMatrix value score: 9.0/10. Overall verdict: Sell.

Q: What do analysts say about IMNM?

20 analysts cover IMNM with a consensus score of 4.3/5. Average price target: $35.

Q: What does Immunome, Inc. do?

Immunome is a clinical-stage oncology company with three clinical assets: varegacestat (Phase 3 RINGSIDE trial positive in desmoid tumors, NDA submission targeted Q2 2026), IM-1021 (ROR1 ADC in Phase 1), and IM-3050 (FAP-targeted radioligand therapy, Phase 1 initiation planned 2026). The company has an accumulated deficit of $728.2M and no product revenues to date. Varegacestat was acquired from Ayala Pharmaceuticals in March 2024.

Oversold Bounce setup

SellVALUE-TRAP 1/5Moderate ConfidenceUpdated 2 days ago (May 18, 2026, 7:06 AM ET)

Healthcare · Biotechnology

Sell if holding. Engine safety override at $20.61: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 4.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality.

$20.61+46.8% A.UpsideScore 5.2/10#87 of 157 Biotechnology

QualityF-score4 / 9FCF yield-5.89%

Stop $19.99Target $30.65(analyst − 13%)A.R:R 4.3:1

Analyst target$35.23+70.9%13 analysts

$30.65our TP

$20.61price

$35.23mean

$40

Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.60, earnings proximity 80d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.

Recent Developments — Immunome, Inc.

Latest news

HC Wainwright & Co. Reiterates Buy on Immunome, Maintains $40 Price Target — benzinga May 13, 2026 positive
Immunome Q1 EPS $(0.48) Beats $(0.57) Estimate — benzinga May 12, 2026 positive
Immunome Submits New Drug Application To FDA For Varegacestat To Treat Desmoid Tumors, Backed By Phase 3 RINGSIDE Trial — benzinga Apr 29, 2026 positive
Immunome Reveals Oral Presentation Of Phase 3 RINGSIDE Data At 2026 ASCO Annual Meeting — benzinga Apr 21, 2026 positive

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards

Recent Analyst detected in news

Risks

Concentration risk — Pipeline: varegacestat

Quality below floor (1.7 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)-10.4

Mkt Cap$2.4B

EV/EBITDA-7.9

Profit Mgn0.0%

ROE-50.1%

Rev Growth—

Beta2.12

DividendNone

Rating analysts20

Quality Signals

Piotroski F4/9

Concentration Risks(10-K Item 1A)

HIGHpipelinevaregacestat
10-K Item 1: 'In December 2025, we announced positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat in patients with progressing desmoid tumors'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers·2 ceiling hits

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value9.015%1.35

Quality1.715%0.26

Growth5.015%0.75

Momentum4.010%0.40

Sentiment8.610%0.86

Insider Activity4.110%0.41

Peer Rank4.810%0.48

Technical Setup7.65%0.38

Risk Profile2.45%0.12

Catalyst3.45%0.17

Overall (Σ contributions)5.17

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe

0.0

Roa

0.0

Gross Margin

0.0

Net Margin

0.0

Fcf Quality

0.0

Moat

4.0

Piotroski F

4.4

Current Ratio

5.0

Cash-burning: FCF -3470% of revenueNo competitive moatQuality concerns

Volatile — 5.5% daily ATR makes tight stops impractical. Position-size conservatively.static

Days To Cover

0.0

Volatility

0.0

Short Interest

1.6

Beta

3.0

Debt Equity

7.2

High short interest justified: 19%Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Surprise Avg

0.0

Earnings History

1.1

Erm

5.0

Earnings Timing

5.0

News Activity

6.0

Earnings concerns: 1B/2M

GatesMomentum 4.0<4.5A.R:R 4.3 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS BOOST ANALYST 0.60EARNINGS PROXIMITY 80d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEAROversold BounceSuitability: Aggressive

RSI

29 · Oversold

↓ 20D MA↓ 50D MA↑ 200D MAGOLDEN CROSSSupport $20.61Resistance $24.90

Price Targets

$20

$31

A.Upside+48.7%

A.R:R4.3:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (1.7 < 4.0)

! Momentum score 4.0/10 — below 4.5 minimum

Earnings

1/4 beats

Next Earnings2026-08-06 (80d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is IMNM stock a buy right now?

Sell if holding. Engine safety override at $20.61: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 4.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality. Chart setup: Oversold RSI 29, near Bollinger lower, volume surge. Prior stop was $19.99. Score 5.2/10, moderate confidence.

What is the IMNM stock price target?

Take-profit target: $30.65 (+46.8% upside). Prior stop was $19.99. Stop-loss: $19.99.

What are the risks of investing in IMNM?

Concentration risk — Pipeline: varegacestat; Quality below floor (1.7 < 4.0).

Is IMNM overvalued or undervalued?

Immunome, Inc. trades at a P/E of N/A (forward -10.4). TrendMatrix value score: 9.0/10. Verdict: Sell.

What do analysts say about IMNM?

20 analysts cover IMNM with a consensus score of 4.3/5. Average price target: $35.

What does Immunome, Inc. do?Immunome is a clinical-stage oncology company with three clinical assets: varegacestat (Phase 3 RINGSIDE trial positive...

Immunome is a clinical-stage oncology company with three clinical assets: varegacestat (Phase 3 RINGSIDE trial positive in desmoid tumors, NDA submission targeted Q2 2026), IM-1021 (ROR1 ADC in Phase 1), and IM-3050 (FAP-targeted radioligand therapy, Phase 1 initiation planned 2026). The company has an accumulated deficit of $728.2M and no product revenues to date. Varegacestat was acquired from Ayala Pharmaceuticals in March 2024.